M&A Deal Summary

Gurnet Point Capital and Novo Holdings A/S Acquire Paratek Pharmaceuticals

On June 6, 2023, private equity firm Gurnet Point Capital and corporate investor Novo Holdings A/S acquired life science company Paratek Pharmaceuticals for 462M USD

Acquisition Highlights
  • This is Gurnet Point Capital’s 5th and Novo Holdings A/S’s 5th transaction in the Life Science sector.
  • This is Gurnet Point Capital’s 3rd and Novo Holdings A/S’s 4th largest (disclosed) transaction.
  • This is Gurnet Point Capital’s 7th and Novo Holdings A/S’s 5th transaction in the United States.
  • This is Gurnet Point Capital’s 1st and Novo Holdings A/S’s 1st transaction in Pennsylvania.

M&A Deal Summary

Date 2023-06-06
Target Paratek Pharmaceuticals
Sector Life Science
Buyer(s) Gurnet Point Capital
Novo Holdings A/S
Deal Type Going Private
Deal Value 462M USD
Advisor(s) Moelis & Co. (Financial)
Ropes & Gray (Legal)

Target

Paratek Pharmaceuticals

King of Prussia, Pennsylvania, United States
Paratek Pharmaceuticals is a bio-pharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek Pharmaceuticals was founded in 1996 and is based in King of Prussia, Pennsylvania.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 2

DESCRIPTION

Gurnet Point Capital is private investment group focused on the healthcare and life sciences sectors. The Firm looks to invest across all stages of product development through to commercialization and does so with an approach that is a hybrid of venture and private equity investing strategies. Gurnet Point Capital was formed in 2015 and is headquartered in Cambridge, Massachusetts.


DEAL STATS #
Overall 7 of 7
Sector: Life Science M&A 5 of 5
Type: Going Private M&A Deals 4 of 4
State: Pennsylvania M&A 1 of 1
Country: United States M&A 7 of 7
Year: 2023 M&A 1 of 1
Size (of disclosed) 3 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-10-20 Corium Innovations

Grand Rapids, Michigan, United States

Corium Innovations is a full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities. Corium Innovations is based in Grand Rapids, Michigan.

Buy -
DESCRIPTION

Novo Holdings A/S is a Danish holding company and the investment arm of the Novo Nordisk Foundation. Novo Holdings' objective is to grow the assets of the Foundation and improve the lives of people around the world. In addition to investing in equity and fixed income securities, Novo Holdings pursues direct investments in life science companies. Novo Holdings A/S was established in 1999 and is headquartered in Hellerup, Denmark.


DEAL STATS #
Overall 10 of 16
Sector: Life Science M&A 5 of 7
Type: Going Private M&A Deals 1 of 2
State: Pennsylvania M&A 1 of 1
Country: United States M&A 5 of 7
Year: 2023 M&A 1 of 2
Size (of disclosed) 4 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-11-02 KabaFusion

Cerritos, California, United States

KabaFusion specializes in IVIG (intravenous immunoglobulin) and home-infusion iv therapy with seven pharmacist-owned, patient-focused specialty pharmacies serving over 40 states across the country. KabaFusion was formed in 2010 and is based in Cerritos, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-06-21 Ellab

Hilleroed, Denmark

Ellab is a manufacturer of solutions for measuring, recording, monitoring, and validating critical parameters of thermal processing. Ellab offers a product range of high-precision systems for temperature, pressure, and humidity monitoring and validation based on either data loggers or thermocouple-based wired instruments. Ellab was founded in 1949 and is based in Hilleroed, Denmark.

Buy -